Skip To Main Content
He-Bing Zhou on Muck Rack

He-Bing Zhou

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with He-Bing

Contact He-Bing, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial

|
By Peng Zhao, Zhuo-Yu An, Hai-Xia Fu, Yang Wang, Hui-Xin Liu, Dai-Hong Liu, Yi Liu, Zhao Wang, Yu-jun Dong, Hong-Mei Jing, Li-Hong Li, Qiu-Sha Huang, Jin Wu Verified, Li-Ping Yang, Yue Jin, Chen-Cong Wang, Qi Chen, Xiao-Lu Zhu, Yun He, Yuan-Yuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, Ying-Jun Chang, Xiang-Yu Zhao, Xiao-Jun Huang, Xiao-Hui Zhang, Guo-Shuang Feng, He-Bing Zhou, Zhen-Ling Li, Li-Ping Dou, Zhi-Xue Li
| Nature Verified
Abstract This multicenter, randomized, controlled study was conducted to explore the safety and efficacy of low-dose baricitinib plus danazol for ITP patients who had failed corticosteroids and at least one recommended subsequent treatment. Participants were randomly assigned to receive baricitinib plus danazol (n = 108) or danazol alone (n = 108) by a central, interactive web-based system. Patients and caregivers were not blinded to group assignment.
Open in Who Shared Issue with article?
See all 1 articles